Biotech Companies Clash Over HPV, HCV Patents

Law360, New York (October 12, 2005, 12:00 AM EDT) -- A bevy of biotech companies are facing off in court over a lucrative technology to detect and treat Human Papilloma Virus and Hepatitis C, two common causes of liver cancer that affect more than one in five young women.

Litigation over HPV and Hepatitis C diagnostics is heating up just as drug maker Merck & Co. is getting ready to apply for U.S. Food and Drug Administration approval for its anti-HPV vaccine Gardasil. In preliminary tests, the treatment has proven to be 100% effective against cervical...
To view the full article, register now.